Women's Health

Summary

This completely updated edition of this comprehensive and indispensable report covers the breadth of traditional IVD testing. The report contains complete market statistics and analysis for all areas of IVD, including:

• Point-of-Care
• Clinical Chemistry
• Immunoassays
• Molecular Assays
• Hematology
• Coagulation
• Microbiology and Virology
• Blood Banking
• Histology and Cytology

Market size, growth, share, and geographic distribution, as well as trends in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Projections are made through 2010.

This new 1,000-page edition greatly expands coverage of the field and tracks the most important developments. Expanded or added in this edition are sections on:

• the movement toward POC and decentralization in lab medicine
• miniaturization and molecularization of devices
• geo-economic and demographic influences on markets
• non-invasive sampling
• greatly expanded market data on PGx and SNP testing
• revamped segmentation for clinical chemistry to include workstations and immunoanalyzers
• more information about more immunoassays
• the renewed interest in microbiology/virology based on resistance and the re-emergence of serious hospital- and community-based organisms
• world blood banking developments
• expanded sections on histology/cytology developments including emerging areas such as tissue microarrays, circulating tumor cells, and genomics-fueled innovation.

In addition, there are now profiles of more than established and emerging players in IVD with profiles of more than 421 companies, from the top tier to emerging and niche competitors to watch.

Contents

Chapter One: Executive Summary

Scope and Methodology
Size and Growth of the Market
Trends Affecting the Market
Market Outlook

Chapter Two: Introduction and Overview

History of Women's Health
Female Reproductive System
Hormone Regulation
Demographics
Epidemiology
o Autoimmune Disease
o Cancer
o Gynecological Infection and Sexually Transmitted Disease
o Hormone-Related Indications
o Osteoporosis
o Urinary Bladder Disorders
o Lifestyle Patterns

Chapter Three: Autoimmune Diseases

Overview
Chronic Fatigue Syndrome
Treatment
Fibromyalgia
Treatment
Rheumatoid Arthritis
Treatment
Scleroderma
Treatment
Sjogren's Syndrome
Treatment
Systemic Lupus Erythematosus
Treatment
Market Size and Growth
Geographical Market Analysis
Research and Development
o 406381
o Anergix RA
o Ampligen
o Actemra
o Apilmod
o Arcoxia
o CDP 870
o CTLA 41G
o Denosumab
o Interleukin (IL-1)
o LymphoStat-B
o MabThera
o Milnacipran
o Prestara
o Prexige
o Prograf
o Org 39141
o Riquent
o Veldona

Competitive Market

Chapter Four: Cancer

Overview
Breast Cancer
o Overview
o Treatment
Cervical Cancer
o Overview
o Treatment
Endometrial Cancer
o Overview
o Treatment
Ovarian Cancer
o Overview
o Treatment
Vaginal Cancer
o Overview
o Treatment
Market Size and Growth
Geographical Market Analysis
Research and Development
o Advexin
o Arzoxifene
o Atamestane
o Avastin
o BrevaRex
o Cervarix
o Combidex
o Edotecarin
o Evista
o Herceptin
o Ixabepilone
o Lapatinib
o Lasofoxifene
o MDX-010
o Myocet
o OvaRex
o Pemtumomab
o Tavocept
o Taxoprexin
o Telcyta
o Temsirolimus
o Tykerb
o Vinorelbine IV
o Xinlay
o XRP 98
o Xytotax
o Yondelis
Competitive Market

Chapter Five: Gynecological Infections and Sexually Transmitted Diseases

Overview
AIDS
o Overview
o Treatment
o Agenerase
o Aptivus
o Combivir
o Crixivan
o Entriva
o Fortovase
o Fuzeon
o Hivid
o Invirase
o Kaletra
o Kivexa
o Lexiva
o Prezista
o Rescriptor
o Reyataz
o Sustiva
o Trizivir
o Truvada
o Viracept
o Viramune
Bacterial Vaginosis
o Overview
o Treatment

Cervical Dysplasia
o Overview
o Treatment
Chlamydia
o Overview
o Treatment
Condyloma Acuminata
o Overview
o Treatment
o Aldara
o Alferon N Injection
o Condylox
o Gardasil
Genital Herpes
o Overview
o Treatment
o Zovirax
Gonorrhea
o Overview
o Treatment
Hepatitis
o Overview
o Treatment
o Baraclude
Pelvic Inflammatory Disease
o Overview
o Treatment
Syphilis
o Overview
o Treatment
Toxic Shock Syndrome
o Overview
o Treatment
Yeast Infections
o Overview
Treatment
Market Size and Growth
Geographical Market Analysis
Research and Development
o Ampligen
o Aplaviroc
o BufferGel
o Carraguard
o Clevudine
o HepeX-B
o Hyphanox
o IFN-alpha Lozenge
o Interferon Alfacon/Ribaviron Combination
o Maraviroc
o Multiferon
o PRO 2000
o Proleukin
o Resiquimod
o SAVVY
o Simplirix
o SPO1A
o Telbivudine
o Ushercell
o Zadaxin
o Competitive Market

Chapter Six: Hormone-Related Disorders

Overview
Contraception
o Overview
o Treatment
o Oral Contraceptives
o Depo-Provera
o Birth Control Patch
o Vaginal Ring
o Emergency Contraception and Early Option
o Implant
o Intrauterine Device (IUD)
Endometriosis
o Overview
o Treatment
Fibroids
o Overview
o Treatment
Infertility
o Overview
o Treatment
Menopause
o Overview
o Treatment
Menstrual Disorders
o Amenorrhea
o Dysmenorrhea
Sexual Dysfunction
o Overview
o Treatment
Market Size and Growth
Geographical Market Analysis
Research and Development
o Alista
o Alprox-TD
o Asoprisnil
o Bijuva
o Bio-E-Gel
o BufferGel
o E2/DNG Pill
o Evamist
o FC Patch
o Femprox Cream
o Intrinsa
o LibiGel
o IoGen
o Lybrel
o Menopausal Levonorgestrel System
o NOMAC/E2
o Preven Emergency Contraceptive Kit
o Tanaproget
o Tostrelle
Competitive Market

Chapter Seven: Osteoporosis

Overview
Market Size and Growth
Geographical Market Analysis
Research and Development
o Aclasta
o AMG 162
o ALX 1-11
o Arzoxifene
o Banzedoxifene
o Denosumab
o Lasofoxifene (Oporia)
o Livial
o Oral Calcitonin
o Ostarine
o Preos
o S12911
Competitive Market

Chapter Eight: Urinary Bladder Disorders

Overview
Cystitis
o Overview
o Treatment
Incontinence
o Overview
o Treatment
o Overactive Bladder
o Treatment
o Alternative Treatments
Interstitial Cystitis
o Overview
o Treatment

Market Size and Growth
Geographical Market Analysis
Research and Development
Competitive Market

Chapter Nine: Issues and Trends

Women's Health Initiative
Perimenopausal Use of Contraceptives
Fosamax Patents Void in European Market
Insurance Coverage for Contraceptives
Oral Contraceptives in Japan
Ovarian Cancer Test
New Pap Test Screening Guidelines
Estrogen Labeling
Osteoporosis Drug Opportunities in Asia
OTC Plan B
Cervical Cancer Vaccines
Women's Access to Health Care and Insurance
Issues of Middle-Aged and Older Women
Possible AIDS Vaccine

Chapter Ten: World Market Summary

Overview
Total Market Size and Forecast
Market Analysis

Chapter Eleven: Competitor Profiles

Industry Structure and Participants
Akzo Nobel nv Organon International
Amgen, Inc.
AstraZeneca PLC
Barr Laboratories, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
GlaxoSmithKline
Johnson & Johnson
Merck & Company, Inc.
Novartis International AG
Pfizer, Inc.
Procter & Gamble Company
Roche
Sanofi -Aventis
Schering AG
Serono International S.A.
Wyeth

Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary
Table 1-1: Market Summary: The Worldwide Market for Prescription Drugs for Women's Healthcare 2000-2010
Figure 1-1: The Market for Women's Healthcare Trending in Revenues by Segment 2000-2010

Chapter Two: Introduction and Overview
Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2005
Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2005 (Difference, in Years, between Females and Males)
Table 2-2: World Population Growth: Total World Population and Selected Country or Regions by Sex, 2000-2025
Figure 2-2: World Population Growth by Sex 2000-2025
Figure 2-3: United States Population Growth by Sex 2000-2025
Figure 2-4: Five Major European Countries* Population Growth by Sex 2000-2025
Figure 2-5: Japan Population Growth by Sex 2000-2025
Table 2-3: World Female Population Growth by Selected Country/Region and Age Group, 2000-2025
Figure 2-6: World Female Population Growth by Selected Age Group 2000-2025
Figure 2-7: United States Female Population Growth by Selected Age Group 2000-2025
Figure 2-8: Five Major European Countries* Female Population Growth by Selected Age Group 2000-2025
Figure 2-9: Japan Female Population Growth by Selected Age Group 2000-2025
Table 2-4: Estimated Female Prevalence of Autoimmune Diseases by Type (Chronic Fatigue Syndrome, Fibromyalgia, Rheumatoid Arthritis, Scleroderma, Sjogren's Disease, Systemic Lupus Erythematosus) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
Table 2-5: Estimated Incidence and Mortality of Female Cancers by Type (Breast, Cervical, Endometrial, Ovarian) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
Table 2-6: Estimated Female Incidence/Prevalence of Gynecological and Sexually Transmitted Diseases by Type ((AIDS/HIV, Bacterial Vaginosis, Cervical Dysplasia, Chlamydia, Genital Herpes, Gonorrhea, Human Papilloma Virus, Hepatitis [Sexually Transmitted], Pelvic Inflammatory Disease, Syphilis, Toxic Shock Syndrome, Yeast Infection) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
Table 2-7: Gynecological and Sexually Transmitted Diseases Diagnostic Testing Procedure Volume by Type (Pap, Pelvic Exams, HIV Tests, Other STD Tests, Mammograms), Five-Year Average 2000-2005
Table 2-8: Estimated World and U.S. Female Incidence/Prevalence of Hormone-Related Indications by Type (Contraception, Endometriosis, Fibroids, Infertility, Menopause), Five-Year Average 2000-2005
Table 2-9: Estimated World and U.S. Contraceptive Use by Method ((Female Sterilization, Oral Pill, Implant, Injectable, IUD, Diaphragm, Female Condom, Other Methods), Five-Year Average 2000-2005
Table 2-10: Estimated Female Prevalence of Osteoporosis by Type (Diagnosed, Low-Bone Mass [At Risk], Osteoporosis-related Fractures) and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005
Table 2-11: Estimated Female Incidence/Prevalence of Urinary Bladder Disorders by Type (UTI, Incontinence, Overactive Bladder, Interstitial Cystititis) and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005
Table 2-12: Estimated Female Statistics Concerning Lifestyle Patterns Contributing to Disease by Type of Behavior and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005

Chapter Three: Autoimmune Diseases
Table 3-1: The World Market for Autoimmune Disease Drugs for Women by Type (Antidepressants, Antianxiety/Sedatives, NSAIDs, Biologicals [RA] Immunosuppressants, Other) 2000-2010
Figure 3-1: The World Market for Autoimmune Disease Drugs for Women Revenues by Type 2000-2010
Figure 3-2: The World Market for Autoimmune Disease Drugs for Women Share by Type (Antidepressants, Antianxiety/Sedatives, NSAIDs, Biologicals [RA] Immunosuppressants, Other) 2005 & 2010
Table 3-2: The World Market for Autoimmune Disease Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
Figure 3-3: The World Market for Autoimmune Disease Drugs for Women Share by Geographic Region 2005 and 2010
Table 3-4: The World Market for Autoimmune Disease Drugs for Women Revenues and Market Share by Supplier 2005
Figure 3-4: The World Market for Autoimmune Disease Drugs for Women Market Share by Leading Supplier 2005

Chapter Four: Cancer
Table 4-1: The World Market for Cancer Drugs for Women by Type (Anti-metabolites, Alkylating Agents, Hormone Therapy, Biologic Therapies) 2000-2010
Figure 4-1: The World Market for Cancer Drugs for Women Revenues by Type 2000-2010
Figure 4-2: The World Market for Cancer Drugs for Women Share by Type 2005 and 2010
Table 4-2: The World Market for Cancer Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
Figure 4-3: The World Market for Cancer Drugs for Women Share Percentage 2005 and 2010
Table 4-3: Products in Development for Women's Cancers (Product, Indication, Developer, Phase) 2005
Table 4-4: The World Market for Cancer Drugs for Women Revenues and Market Share by Supplier 2005
Figure 4-4: The World Market for Cancer Drugs for Women Market Share by Leading Supplier 2005

Chapter Five: Gynecological Infections and Sexually Transmitted Diseases
Table 5-1: Currently Available HIV Pharmaceuticals
Table 5-2: Currently Marketed Bacterial Vaginosis Pharmaceuticals
Table 5-3: Currently Marketed Chlamydia Pharmaceuticals
Table 5-4: Currently Marketed Condyloma Treatments
Table 5-5: Currently Marketed Herpes Virus Treatments
Table 5-6: Currently Marketed Hepatitis Treatments
Table 5-7: Currently Marketed PID Treatments
Table 5-8: Currently Marketed Prescription Yeast Infection Treatments
Table 5-9: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women by Type (Antibacterials, Antifungals, Antivirals) 2000-2010
Figure 5-1: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Type 2000-2010
Figure 5-2: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Type 2005 and 2010
Table 5-10: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
Figure 5-3: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Geographic Region 2005 and 2010
Table 5-11: Products in Development for Women's Gynecological Infections and Sexually Transmitted Diseases (Product, Indication, Developer, Phase)
Table 5-12: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues and Market Share by Supplier 2005
Figure 5-4: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Market Share by Leading Supplier 2005

Chapter Six: Hormone-Related Disorders
Table 6-1: Selected Oral Contraceptives Available 2005
Table 6-2: Selected Hormone Replacement Therapies
Table 6-3: The World Market for Hormone-Related Disorder Drugs for Women by Type (Contraceptives, Infertility Agents, Hormone Replacents, Other Hormone Therapies) 2000-2010
Figure 6-1: The World Market for Hormone-Related Disorder Drugs for Women by Type 2000-2010
Figure 6-2: The World Market for Hormone-related Disorder Drugs for Women Share by Type 2005 and 2010
Table 6-4: The World Market for Hormone-Related Disorder Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
Figure 6-3: The World Market for Hormone-Related Disorder Drugs for Women Share by Geographic Region 2005 and 2010
Table 6-5: Hormonal Preparations in Research and Development for Women (Product, Indication, Developer, Phase)
Table 6-6: The World Market for Hormone-Related Disorder Drugs for Women Revenues and Market Share by Supplier 2005
Figure 6-4: The World Market for Hormone-Related Disorder Drugs for Women Market Share by Leading Supplier 2005

Chapter Seven: Osteoporosis
Table 7-1: The World Market for Osteoporosis Drugs for Women Revenues by Type (Bone Metabolism Regulators, Hormones/SERMs) 2000-2010
Figure 7-1: The World Market for Osteoporosis Drugs for Women Revenues by Type 2000-2010
Figure 7-2: The World Market for Osteoporosis Drugs for Women Share by Type 2005 and 2010
Table 7-2: The World Market for Osteoporosis Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
Figure 7-3: The World Market for Osteoporosis Drugs for Women Share by Geographic Region 2005 and 2010 Table 7-3: Products in Development for Osteoporosis (Product, Developer, Phase)
Table 7-4: The World Market for Osteoporosis Drugs for Women Revenues and Market Share by Supplier 2005
Figure 7-4: The World Market for Osteoporosis Drugs for Women Market Share by Leading Supplier 2005

Chapter Eight: Urinary Bladder Disorders < r> Table 8-1: Medications That Can Affect Urination
Table 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type (Antibiotics, Anticholinergics/Antispasmodics, Cholinergics, Other) 2000-2010
Figure 8-1: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type 2000-2010
Figure 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Share by Type 2005 and 2010
Table 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
Figure 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Share by Geographic Region 2005 and 2010
Table 8-4: Products in Development for Urinary Disorders (Product, Indication, Developer, Phase)
Table 8-5: The World Market for Urinary Bladder Disorder Drugs for Women Revenues and Market Share by Supplier 2005
Figure 8-4: The World Market for Urinary Bladder Disorder Drugs for Women Market Share by Leading Supplier 2005

Chapter Ten: World Market Summary
Table 10-1: The Worldwide Market for Prescription Drugs in Women's Health, Revenues by Segment (Autoimmune, Cancer, Gynecologic Infections and STDs, Hormones, Osteoporosis, Urinary Bladder Disorders), 2000-2010
Figure 10-1: The Market for Women's Healthcare Revenues by Segment 2000-2010
Figure 10-2: The Market for Women's Healthcare Market Share by Type 2005 and 2010
Table 10-2: Women's Health Revenues and Segments of Participation by Leading Market Participants 2005